Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 14/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825911 | 0.85 | CYP19A1 (0.54) | GBA1CYP19A1 | |
| SCHEMBL19509621 | 0.83 | NOTUM (0.53) | GBA1NOTUM | |
| SCHEMBL24023176 | 0.83 | — | — | |
| SCHEMBL1753962 | 0.83 | GBA1 (0.45) | GBA1CYP19A1 | |
| SCHEMBL14020289 | 0.83 | MAPT (0.44) | GBA1 | |
| SCHEMBL23081527 | 0.82 | GBA1 (0.52) | GBA1CYP19A1 | |
| SCHEMBL16029999 | 0.82 | POLB (0.48) | GBA1NOTUMCYP19A1 | |
| SCHEMBL12299387 | 0.82 | GBA1 (0.51) | GBA1SMPD1 | |
| SCHEMBL12299383 | 0.82 | GBA1 (0.51) | GBA1SMPD1 | |
| SCHEMBL12825189 | 0.81 | MAOB (0.43) | GBA1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3099668-B1 | 5-BIPHENYL-4-HETEROARYLCARBONYLAMINO-PENTANOIC ACID DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3763813-A1 | ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2021-01-13 | — | — | EP | disclosed |
| US-9926298-B2 | Heterocyclic compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2018-03-27 | — | — | US | disclosed |
| US-20180009786-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2018-01-11 | — | — | US | disclosed |
| US-9862703-B2 | Heterocyclic compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2018-01-09 | — | — | US | disclosed |
| US-20160083369-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-03-24 | — | — | US | disclosed |
| WO-2012030683-A2 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011029639-A2 | COMPOUNDS AND METHODS FOR TREATING NEOPLASIA | MEDEXIS S.A. (GR) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009786-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | CXCL12, HPGDS, MCL1 | GBA1 2284/4885NOTUM 2711/4885CYP19A1 367/4885 |
| US-20160083369-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | CXCL12, HPGDS, MCL1 | GBA1 2284/4885NOTUM 2711/4885CYP19A1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.